Skip to main content

Main menu

  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us

Clinical Medicine Journal

  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

User menu

  • Log in

Search

  • Advanced search
RCP Journals
Home
  • Log in
  • Home
  • Our journals
    • Clinical Medicine
    • Future Healthcare Journal
  • Subject collections
  • About the RCP
  • Contact us
Advanced

Clinical Medicine Journal

clinmedicine Logo
  • ClinMed Home
  • Content
    • Current
    • Ahead of print
    • Archive
  • Author guidance
    • Instructions for authors
    • Submit online
  • About ClinMed
    • Scope
    • Editorial board
    • Policies
    • Information for reviewers
    • Advertising

Beware of thromboembolic risk in obese patients on direct oral anticoagulants (DOACs)

Indrajit Chattopadhyay, Vedamurthy Adhiyaman and Suhani Ghiya
Download PDF
DOI: https://doi.org/10.7861/clinmedicine.18-3-267
Clin Med June 2018
Indrajit Chattopadhyay
Glan Clwyd Hospital, Rhyl, UK
Roles: Consultant geriatrician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vedamurthy Adhiyaman
Glan Clwyd Hospital, Rhyl, UK
Roles: Consultant geriatrician
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suhani Ghiya
Glan Clwyd Hospital, Rhyl, UK
Roles: Clinical pharmacist
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Editor – We read with interest the article by Burden et al on pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine.1 While the authors highlight the interaction between rivaroxaban and carbamazepine, one should be mindful of other risk factors that might reduce the therapeutic efficacy of a direct oral anticoagulant (DOAC), namely severe obesity, possibly due to suboptimal dosing regime in such patients.

We encountered an elderly woman with severe obesity (body weight: 120.95 kg, body mass index [BMI] 44 kg/m2] who presented with pleuritic chest pain. She was taking apixaban 5 mg twice daily for atrial fibrillation. CT pulmonary angiogram confirmed an acute pulmonary embolus. There were no other risk factors and we felt that the reason for her suboptimal anticoagulation was severe obesity as this could have led to higher volume of distribution and lower mean peak concentration of apixaban.2 We stopped the apixaban and treated her with warfarin.

Studies using DOACs have had fewer obese or morbidly obese patients and only a few had analysed the effect of weight on the pharmacokinetic and pharmacodynamic properties of DOACs. Results indicated that patients with higher body weights had lower peak concentrations, increased volume of distribution and shorter half-lives of DOACs.3,4

Although dose adjustment of DOACs in severely obese patients are still not recommended on the product literature, expert guidance suggests avoiding DOACs in patients with a BMI of >40 kg/m2, or a weight of >120 kg.4 If DOACs are used in such patients, they recommend checking drug-specific peak and trough levels and substituting it with a vitamin K antagonist if the levels are below the expected range, rather than adjusting the DOAC dose.4

It is important to raise awareness of clinicians on this matter as venous and arterial thromboembolic events while taking DOACs account for 3–5% of adverse events that are reported to the Medicines and Healthcare products Regulatory Agency (MHRA).5 While there is a need for more data on the efficacy of DOACs on obese patients, we also need guidance on the most appropriate anticoagulation regime for patients who suffer a thromboembolic episode despite being on a DOAC.

  • © Royal College of Physicians 2018. All rights reserved.

References

  1. ↵
    1. Burden T
    , Thompson C, Bonanos E, Medford ARL. Lesson of the month 2: Pulmonary embolism in a patient on rivaroxaban and ­concurrent carbamazepine. Clin Med 2018;18:103–5.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Upreti VV
    , Wang J, Barrett YC, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 2013;76:908–16.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Güler E
    , Güler GB, Demir GG, Halipo˘glu S. A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough? Anatol J Cardiol 2015;15:1020–9.
    OpenUrl
  4. ↵
    1. Martin K
    , Beyer-Westendorf J, Davidson BL, et al. Use of direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016;14:1308–13.
    OpenUrlCrossRefPubMed
  5. ↵
    Medicines and Healthcare products Regulatory Agency. Yellow card scheme. https://yellowcard.mhra.gov.uk [Accessed 3 March 2018].
Back to top
Previous articleNext article

Article Tools

Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Beware of thromboembolic risk in obese patients on direct oral anticoagulants (DOACs)
Indrajit Chattopadhyay, Vedamurthy Adhiyaman, Suhani Ghiya
Clinical Medicine Jun 2018, 18 (3) 267; DOI: 10.7861/clinmedicine.18-3-267

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Beware of thromboembolic risk in obese patients on direct oral anticoagulants (DOACs)
Indrajit Chattopadhyay, Vedamurthy Adhiyaman, Suhani Ghiya
Clinical Medicine Jun 2018, 18 (3) 267; DOI: 10.7861/clinmedicine.18-3-267
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • Info & Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • ADHD in obesity clinics: common, often missed, highly treatable
  • Streams, rivers and data lakes: an introduction to understanding modern electronic healthcare records
  • Assessment of obesity
Show more Letters to the editor

Similar Articles

FAQs

  • Difficulty logging in.

There is currently no login required to access the journals. Please go to the home page and simply click on the edition that you wish to read. If you are still unable to access the content you require, please let us know through the 'Contact us' page.

  • Can't find the CME questionnaire.

The read-only self-assessment questionnaire (SAQ) can be found after the CME section in each edition of Clinical Medicine. RCP members and fellows (using their login details for the main RCP website) are able to access the full SAQ with answers and are awarded 2 CPD points upon successful (8/10) completion from:  https://cme.rcplondon.ac.uk

Navigate this Journal

  • Journal Home
  • Current Issue
  • Ahead of Print
  • Archive

Related Links

  • ClinMed - Home
  • FHJ - Home
clinmedicine Footer Logo
  • Home
  • Journals
  • Contact us
  • Advertise
HighWire Press, Inc.

Follow Us:

  • Follow HighWire Origins on Twitter
  • Visit HighWire Origins on Facebook

Copyright © 2023 by the Royal College of Physicians